Last reviewed · How we verify
AeroFact
AeroFact is a medication that helps to improve lung function in patients with chronic obstructive pulmonary disease (COPD) by facilitating the delivery of inhaled medications.
AeroFact is a medication that helps to improve lung function in patients with chronic obstructive pulmonary disease (COPD) by facilitating the delivery of inhaled medications. Used for Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | AeroFact |
|---|---|
| Also known as | SF-RI 1 |
| Sponsor | Aerogen Pharma Limited |
| Drug class | inhaled medication delivery device |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
AeroFact is a device that uses a combination of heat and air flow to liquefy medications, making it easier to inhale them. This can help to improve lung function and reduce symptoms in patients with COPD.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Cough
- Dyspnea
- Wheezing
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AeroFact CI brief — competitive landscape report
- AeroFact updates RSS · CI watch RSS
- Aerogen Pharma Limited portfolio CI